Company news

Praxis Precision Medicines, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences

March 3, 2025

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

February 27, 2025

Praxis Precision Medicines to Present at Two February Investor Conferences

February 2, 2025

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

January 11, 2025

Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference

January 5, 2025

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

December 17, 2024

Praxis Precision Medicines to Present at Upcoming December Investor Conferences

December 2, 2024

Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting

November 25, 2024

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

November 5, 2024

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

November 5, 2024

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

October 31, 2024

Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress

September 25, 2024

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

September 3, 2024

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

September 2, 2024

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

September 1, 2024

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results

August 12, 2024

Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

August 4, 2024

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 12, 2024

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

May 9, 2024

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

April 11, 2024

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

March 27, 2024

Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients

March 25, 2024

Praxis Precision Medicines to Host PRAX-628 Program Update

March 24, 2024

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

March 4, 2024

Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference

February 29, 2024

Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering

January 10, 2024

Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio

January 7, 2024

Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China

January 4, 2024

Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings

November 27, 2023

Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference

November 20, 2023

Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

November 15, 2023

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 6, 2023

Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium

November 1, 2023

Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day

October 1, 2023

Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023

September 26, 2023

Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference

September 6, 2023

Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress

August 30, 2023

Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress

August 27, 2023

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results

August 8, 2023

Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide

August 7, 2023

Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study

August 6, 2023

Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference

August 2, 2023

Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities

June 21, 2023

Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering

June 14, 2023

Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA

June 8, 2023

Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference

June 1, 2023

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 10, 2023

Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile

May 10, 2023

Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting

April 18, 2023

Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events

April 16, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 9 calls. Every call is listed under its year.

Decks

The 5 newest of 35 decks. Every deck is listed under its year.